Abstract
Objectives To determine predictors of tissue that would benefit from improved blood flow in subjects with advanced heart disease.
Background Advanced regeneration and percutaneous revascularization strategies including revascularization of chronic total occlusions (CTO) are being used to potentially restore myocardial function in the growing population of patients with advanced heart disease. Predictors of myocardial recovery in this population have not been established.
Methods Cardiac tissue was collected from 27 subjects undergoing LVAD or cardiac transplantation who had nuclear perfusion imaging prior to procedure. Histologic analysis for fibrosis, vascular density and inflammation was performed and correlated with nuclear perfusion images from the same areas. In a subset of subjects, correlations of nuclear perfusion with TIMI flow by coronary arteriography was also performed.
Results Areas of both normal and abnormal epicardial coronary blood flow had a large variation in radiotracer uptake. There were no statistically significant correlations between uptake of radiotracer at rest and degree of cardiac fibrosis, vascular density or inflammation and the matched area of myocardium. Fibrosis varied from 5-50% in areas with severe defects and areas of normal radiotracer uptake. Endothelial density correlated with inflammation in end-stage heart disease.
Conclusions Radiotracer uptake poorly predicted both areas of severe fibrosis that will not benefit from increased blood flow and areas of minimal fibrosis that may recover. Correlation of inflammation and endothelial density support a hypothesis that inflammatory cytokines augment vascularity in myocardium. Novel strategies to improve function in advanced heart disease are in need of better markers of recovery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R01HL094384 UL1TR000423 ITHS ACC Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Washington Human Subjects Division
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grants: This work was supported by R01 HL094384 and Tall Family Foundation (ASO), UL1TR000423 ITHS (CD), Locke Family Foundation (ASO and SDF) and American College of Cardiology Foundation Fellowship (SDF).
Industry Relationships: WL-Consulting for Corindus Equity, Abbott Vascular, Boston Scientific, Asahi Intec, Teleflex, Seimens; CD-Consulting for Abiomed, Spectranetics, Abbott, CSI; SF, LS, JC, and ASO-none
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.